Akronia Valley

Akronia Valley is a Spanish biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting G protein-coupled receptors (GPCRs). The company utilizes a proprietary drug discovery platform that combines advanced computational modeling with specialized biological assays to identify high-affinity ligands for challenging GPCR targets. Their primary research programs are directed toward addressing significant unmet needs in neuropathic pain and inflammatory disorders. By leveraging their expertise in receptor pharmacology, Akronia Valley aims to develop next-generation treatments with improved efficacy and reduced side-effect profiles compared to current standards of care.